Latest Share Chat

REMOVE ADS

Shield Thera Share News (STX)

Shield Thera Information

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes

Get Live Data

5.75 -0.10 (-1.71%)

Bid:

5.70

Ask:

5.80

Spread: 0.10 (1.754%)

Market Cap: £61.50m

Last checked at -

Intraday Shield Thera Share Chart

REMOVE ADS

Shield Thera News

EARNINGS AND TRADING: Peel Hunt upbeat; Transense cuts profit outlook

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported...

Shield Therapeutics reaches cash flow positivity as revenue grows

(Alliance News) - Shield Therapeutics PLC on Wednesday said it achieved operating cash flow positivity in the fourth quarter of 2025, as it guided an ...

EARNINGS AND TRADING: Corel loss widens; Christie sells Vennersys

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported...

Shield Therapeutics upbeat as Accrufer trial initiated in Japan

(Alliance News) - Shield Therapeutics PLC on Friday reported the commencement of a phase two Accrufer trial in Japan for the treatment of pulmonary ar...

IN BRIEF: Shield receives approval from South Korea for Accrufer

(Alliance News) - Shield Therapeutics PLC - Newcastle, England-based commercial-stage pharmaceutical company - Announces that the Korean Ministry of F...

TRADING UPDATES: Shoe Zone wary ahead of budget; Nexus sales jump 16%

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Shield Therapeutics reports strongest quarterly performance to date

(Sharecast News) - Shield Therapeutics reported its strongest quarterly performance to date on Thursday, with third-quarter Accrufer prescriptions ris...

Shield Therapeutics reports positive results in paediatric trial

(Alliance News) - Shield Therapeutics PLC on Wednesday noted positive efficacy and tolerance results from in its phase three ferric maltol Fortis tria...